Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 226


Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.

Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Buyse M, de Gramont A.

J Clin Oncol. 2003 Aug 1;21(15):2896-903.


Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.

André T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O, Achille E, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Lledo G, Raoul Y, Debrix I, Buyse M, de Gramont A.

J Clin Oncol. 2007 Aug 20;25(24):3732-8.


Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: study design and preliminary safety results. Groupe d'Etude et de Recherche Clinique en Oncologie Radiotherapies.

André T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, Colbert N, Boaziz C, Piedbois P, Tubiana-Mathieu N, Boutan-Laroze A, Flesch M, Billiau V, Buyse M, Gramont A; Groupe d'Etude et de Recherche Clinique en Oncologie Radiotherapies.

Semin Oncol. 2001 Feb;28(1 Suppl 1):35-40.


Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma.

Labianca R, Fossati R, Zaniboni A, Torri V, Marsoni S, Nitti D, Boffi L, Scatizzi M, Tardio B, Mastrodonato N, Banducci S, Consani G, Pancera G; ACOI/GIVIO/GISCAD Investigators.

J Natl Cancer Inst. 2004 May 19;96(10):750-8.


Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N.

J Clin Oncol. 2007 Jun 1;25(16):2198-204. Epub 2007 Apr 30.


Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.

Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, Brandt DS, Polikoff J, Wertheim M, Shumaker G, Hallman D, Burger B, Gupta S.

J Clin Oncol. 2004 Dec 1;22(23):4753-61. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.


Leucovorin and fluorouracil vs levamisole and fluorouracil as adjuvant chemotherapy in rectal cancer.

Tsavaris N, Gennatas K, Kosmas C, Skopelitis HM, Gouveris P, Dimitrakopoulos A, Zacharakis M, Kouraklis G, Vasiliou J, Felekouras E, Voros D, Zografos G, Balafouta M, Paraskevaidis M, Safioleas M, Fotiadis K, Papastratis G, Karatzas G, Papalambros E.

Oncol Rep. 2004 Oct;12(4):927-32.


Comparison of the levogyre and dextro-levogyre forms of leucovorin in a phase III trial of bimonthly LV5FU2 versus monthly 5-fluorouracil and high-dose leucovorin for patients with stage II and III colon cancer (GERCOR C96.1).

Baumgaertner I, Quinaux E, Khalil A, Louvet C, Buyse M, de Gramont A, André T; GERCOR Group.

Clin Colorectal Cancer. 2010 Apr;9(2):E5-10. doi: 10.3816/CCC.2010.n.027.


Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.

Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N.

J Clin Oncol. 2006 May 1;24(13):2059-64.


Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.

Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, Mayer RJ.

J Clin Oncol. 2005 Dec 1;23(34):8671-8.


Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome.

Pucciarelli S, Toppan P, Friso ML, Russo V, Pasetto L, Urso E, Marino F, Ambrosi A, Lise M.

Dis Colon Rectum. 2004 Nov;47(11):1798-807.


Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.

Smith RE, Colangelo L, Wieand HS, Begovic M, Wolmark N.

J Natl Cancer Inst. 2004 Aug 4;96(15):1128-32.


Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.

Chakravarthy A, Abrams RA, Yeo CJ, Korman LT, Donehower RC, Hruban RH, Zahurek ML, Grochow LB, O'Reilly S, Hurwitz H, Jaffee EM, Lillemoe KD, Cameron JL.

Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1089-96.


Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.

Cascinu S, Labianca R, Barone C, Santoro A, Carnaghi C, Cassano A, Beretta GD, Catalano V, Bertetto O, Barni S, Frontini L, Aitini E, Rota S, Torri V, Floriani I; Italian Group for the Study of Digestive Tract Cancer, Pozzo C, Rimassa L, Mosconi S, Giordani P, Ardizzoia A, Foa P, Rabbi C, Chiara S, Gasparini G, Nardi M, Mansutti M, Arnoldi E, Piazza E, Cortesi E, Pucci F, Silva RR, Sobrero A, Ravaioli A.

J Natl Cancer Inst. 2007 Apr 18;99(8):601-7.


Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer.

Sobrero A, Frassineti G, Falcone A, Dogliotti L, Rosso R, Di Costanzo F, Bruzzi P; INTACC.

Br J Cancer. 2005 Jan 17;92(1):24-9. Erratum in: Br J Cancer. 2005 Sep 19;93(6):733. Costanzo, FD [corrected to Di Costanzo, F].


A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.

Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thödtmann R, Tschmelitsch J, Jagoditsch M, Steger GG, Jakesz R, Herbst F, Hofbauer F, Rabl H, Wohlmuth P, Gnant M, Thaler J; Austrian Breast and Colorectal Cancer Study Group.

Br J Cancer. 2007 Oct 22;97(8):1021-7. Epub 2007 Sep 25.

Supplemental Content

Support Center